LH 注射適用於高齡及卵巢反應不佳之IVF病患

Fertil Steril. 2018 Apr;109(4):644-664. doi: 10.1016/j.fertnstert.2018.01.003.

Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review.

Alviggi C1, Conforti A2, Esteves SC3, Andersen CY4, Bosch E5, Bühler K6, Ferraretti AP7, De Placido G2, Mollo A2, Fischer R8, Humaidan P9; International Collaborative Group for the Study of r-hLH (iCOS-LH).

Author information

Abstract

OBJECTIVE:

To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients.

DESIGN:

Systematic review.

SETTING:

Centers for reproductive care.

PATIENT(S):

Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a "poor response" to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria.

INTERVENTION(S):

Systematic review.

MAIN OUTCOME MEASURE(S):

Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes.

RESULT(S):

Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36-39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation.

CONCLUSION(S):

Recombinant hLH can be proposed for hyporesponders and women 36-39 years of age.